Condition
EoE
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Active Not Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05543512Not ApplicableCompleted
The Immune Directed Individualized Elimination Therapy (iDIET) Study
NCT06352073Phase 4Active Not Recruiting
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT03656380Phase 2CompletedPrimary
Mepo for Eosinophilic Esophagitis (EoE) Study
NCT02114606Not ApplicableTerminated
Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge
Showing all 4 trials